Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISION pro-drugs and Affimer immunotherapies.

From Avacta Life Sciences Ltd. 13 Aug 2020

Screening for malnutrition may help identify ACS patients at high risk of adverse outcomes

In a study published today in the Journal of the American College of Cardiology of more than 5,000 acute coronary syndromes (ACS) patients, 71.8% were considered malnourished by at least one nutrition screening test, and worsening malnutrition status was associated with higher mortality and major adverse cardiovascular events (MACE), such as another heart attack or stroke.

10 Aug 2020

Kids with silent malaria remain vulnerable to developing endemic Burkitt lymphoma

A study has found strong similarities between children with endemic Burkitt lymphoma — an aggressive cancer that attacks the body's defense system and children with silent malaria infection.

10 Aug 2020

Multiple, intertwined cell death systems to prevent the spread of 'intracellular' bacteria

Melbourne researchers have revealed the multiple, intertwined cell death systems that prevent the spread of the 'intracellular' bacterium Salmonella, an important cause of typhoid fever which kills more than 100,000 people annually.

30 Jul 2020

Clinical study evaluates potential of oral cancer drug to reduce respiratory symptoms of COVID-19

Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a new clinical trial to determine if an oral cancer drug called ibrutinib can also help patients with cancer or other immunocompromised conditions recover from COVID-19.

29 Jul 2020

Combination of certain drugs can do more harm than good, shows study

A team of researchers at the Norwegian University of Science and Technology (NTNU) investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.

29 Jul 2020

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.

28 Jul 2020

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.

27 Jul 2020

First CAR T-cell therapy for mantle cell lymphoma receives FDA approval

Today's Food and Drug Administration approval of the first CAR T-cell therapy for mantle cell lymphoma represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.

24 Jul 2020

Combining two immunotherapies into a single treatment found to be more effective

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer. But immunotherapies don't work in all patients, and researchers have been searching for ways to increase their effectiveness.

23 Jul 2020

Reactivation of divergent signaling pathways can be leveraged to enhance cancer treatment

In order for cancer to form in the human body, normal cells must acquire multiple mutations before they develop toward the disease.

23 Jul 2020

Guidelines for making neutering decision

Some dog breeds have higher risk of developing certain cancers and joint disorders if neutered or spayed within their first year of life. Until now, studies had only assessed that risk in a few breeds.

16 Jul 2020

Study identifies possible factors to predict severe toxicities in CAR T patients

Chimeric antigen receptor T-cell therapy (CAR T) has proved to be a valuable treatment option for patients with lymphoma who have failed other therapies. In clinical trials, the cellular immunotherapy was shown to provide durable remissions for nearly 40% of large B cell lymphoma patients.

15 Jul 2020

Anaplastic large cell lymphoma: Defense mechanism against certain drugs promotes cancer growth

A general problem encountered in cancer therapy is that many patients develop resistance to a drug over the course of treatment.

15 Jul 2020

Dual inhibitor therapy may be safer for CLL patients, Moffitt study shows

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL.

14 Jul 2020

New cancer vaccine shows promising signs in preclinical studies

Scientists are ready to trial a new cancer vaccine in humans following the successful outcome of their preclinical studies.

9 Jul 2020

Mapping immune landscape of hematological malignancies may help improve cancer therapies

Activating the immune system of the body is a promising form of treatment for cancer. Researchers at the University of Helsinki and Helsinki University Hospital as well as the University of Eastern Finland mapped out the immune landscape of hematological malignancies in a dataset covering more than 10,000 patients to identify drug targets and patient groups which could potentially benefit from immunotherapies.

9 Jul 2020

Breast cancer simulation models can guide screening recommendations for women

Chest radiation is used to treat children with Hodgkin and non-Hodgkin lymphoma as well as lung metastases in various solid tumors.

9 Jul 2020

Lymphoma News and Research

Further Reading

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Screening for malnutrition may help identify ACS patients at high risk of adverse outcomes

Kids with silent malaria remain vulnerable to developing endemic Burkitt lymphoma

Multiple, intertwined cell death systems to prevent the spread of 'intracellular' bacteria

Clinical study evaluates potential of oral cancer drug to reduce respiratory symptoms of COVID-19

Combination of certain drugs can do more harm than good, shows study

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

First CAR T-cell therapy for mantle cell lymphoma receives FDA approval

Combining two immunotherapies into a single treatment found to be more effective

Reactivation of divergent signaling pathways can be leveraged to enhance cancer treatment

Guidelines for making neutering decision

Study identifies possible factors to predict severe toxicities in CAR T patients

Anaplastic large cell lymphoma: Defense mechanism against certain drugs promotes cancer growth

Dual inhibitor therapy may be safer for CLL patients, Moffitt study shows

New cancer vaccine shows promising signs in preclinical studies

Mapping immune landscape of hematological malignancies may help improve cancer therapies

Breast cancer simulation models can guide screening recommendations for women

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News